Ikarian Capital, LLC has filed its 13F form on February 14, 2025 for Q4 2024 where it was disclosed a total value porftolio of $606 Million distributed in 171 stocks.
Among their holdings, we can observe that their the top five positions include companies like: Tarsus Pharmaceuticals, Inc. with a value of $33.6M, Crinetics Pharmaceuticals, Inc. with a value of $26.4M, Scholar Rock Holding Corp with a value of $15.4M, Blueprint Medicines Corp with a value of $14.8M, and Viridian Therapeutics, Inc.\De with a value of $9.01M.
Examining the 13F form we can see an increase of $33.4M in the current position value, from $573M to 606M.
Ikarian Capital, LLC is based out at Dallas, TX
Below you can find more details about Ikarian Capital, LLC portfolio as well as his latest detailed transactions.
Portfolio value
$606 Million
Healthcare: $418 Million
ETFs: $131 Million
Consumer Defensive: $57.5 Million
Stock Holdings Table Market Cap. of $50 Millions to $300 Millions
